In a nuclear emergency, a medicine to cure ailments brought on by radioactive radiation was purchased with $290 million, according to a statement from the US Department of Health and Human Services (HHS). According to Al Arabiya, the ministry’s Strategic Preparedness and Response Department stated in a statement released on Tuesday that it has acquired Nplate from Amgen USA Inc. “as part of a long-running endeavour to better prepare to save lives in radiological and nuclear situations.”
A high radiation dose can result in acute radiation sickness, which can manifest as a variety of symptoms. According to the Centers for Disease Control and Prevention, severe cases can have devastating effects on the body, including damaging bone marrow and causing internal bleeding.
The goal of the medication Nplate, which is appropriate for both adults and children, is to lessen bleeding frequently brought on by radiation.
The medicine was initially given approval by the Food and Drug Administration in 2008 to treat an autoimmune condition that can result in life-threatening bleeding, and a second approval for its use as radiation therapy was granted in January of last year.
The new agreement follows a rise in global apprehension over the potential use of nuclear weapons in Russia’s conflict with Ukraine.
For usage in nuclear emergencies, America spends millions of dollars on medications.
About Author
